HomeCompareORAGF vs MRK

ORAGF vs MRK: Dividend Comparison 2026

ORAGF yields 20618.56% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORAGF wins by $71012778431709020160.00M in total portfolio value
10 years
ORAGF
ORAGF
● Live price
20618.56%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71012778431709020160.00M
Annual income
$70,341,670,773,003,646,000,000,000.00
Full ORAGF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — ORAGF vs MRK

📍 ORAGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORAGFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORAGF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORAGF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORAGF
Annual income on $10K today (after 15% tax)
$1,752,577.32/yr
After 10yr DRIP, annual income (after tax)
$59,790,420,157,053,100,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, ORAGF beats the other by $59,790,420,157,053,100,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORAGF + MRK for your $10,000?

ORAGF: 50%MRK: 50%
100% MRK50/50100% ORAGF
Portfolio after 10yr
$35506389215854510080.00M
Annual income
$35,170,835,386,501,823,000,000,000.00/yr
Blended yield
99.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ORAGF
No analyst data
Altman Z
-726.0
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORAGF buys
0
MRK buys
0
No recent congressional trades found for ORAGF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORAGFMRK
Forward yield20618.56%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$71012778431709020160.00M$56.8K
Annual income after 10y$70,341,670,773,003,646,000,000,000.00$9,798.13
Total dividends collected$70968508741613305856.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ORAGF vs MRK ($10,000, DRIP)

YearORAGF PortfolioORAGF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,072,556$2,061,855.67$11,206$366.19+$2.06MORAGF
2$401,592,463$399,374,828.04$12,650$502.35+$401.58MORAGF
3$72,752,675,032$72,322,971,097.28$14,407$694.19+$72752.66MORAGF
4$12,322,763,747,227$12,244,918,384,942.29$16,585$967.82+$12322763.73MORAGF
5$1,951,531,225,653,276$1,938,345,868,443,743.20$19,342$1,363.89+$1951531225.63MORAGF
6$288,977,786,395,286,000$286,889,647,983,837,020.00$22,913$1,947.19+$288977786395.26MORAGF
7$40,011,907,431,485,830,000$39,702,701,200,042,880,000.00$27,662$2,823.89+$40011907431485.81MORAGF
8$5,180,422,024,512,091,000,000$5,137,609,283,560,401,000,000.00$34,159$4,173.35+$5180422024512091.00MORAGF
9$627,203,419,350,822,600,000,000$621,660,367,784,594,700,000,000.00$43,337$6,308.80+$627203419350822656.00MORAGF
10$71,012,778,431,709,020,000,000,000$70,341,670,773,003,646,000,000,000.00$56,776$9,798.13+$71012778431709020160.00MORAGF

ORAGF vs MRK: Complete Analysis 2026

ORAGFStock

Monarca Minerals Inc., a mining company, engages in the acquisition, exploration, and development of silver projects in Mexico. Its flagship property is the Tejamen silver property consisting of 23 mineral concessions covering an area of approximately 1,685 hectares located to the northwest of Durango. The company also has an option agreement to acquire a 100% interest in the San Jose Project covering approximately an area of 5,580 hectares located in Chihuahua, northern Mexico. In addition, it holds 100% interest in the San Lucas property consists of 8 mineral concessions covering 79.6 hectares located to the north of the city of Durango. The company was formerly known as Oremex Silver Inc. and changed its name to Monarca Minerals Inc. in August 2016. Oremex Silver Inc. was incorporated in 1995 and is based in Toronto, Canada.

Full ORAGF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this ORAGF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORAGF vs SCHDORAGF vs JEPIORAGF vs OORAGF vs KOORAGF vs MAINORAGF vs JNJORAGF vs ABBVORAGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.